01/12/2015 - General information
The co-existence of mental illness and psychoactive drug or other substance use problems — otherwise known as ‘comorbidity’ or ‘dual diagnosis’ — is an issue which has been on the radar of the EU drugs agency (EMCDDA) for over a decade. This agency aims to provide objective and reliable information concernint drugs and their consequences.
Més informació "New EMCDDA report explores combined mental health and substance use disorders"
18/09/2015 - General information
Some time ago it was believed that new genes originated, at least partially, from other genes; for instance, from the duplication of existing genes. But recently it has been seen that there are certain genes, those called de novo genes, that originate in genomic regions that didn’t contain any genes previously. A study published in arXiv.org, led by Mar Albà, the coordinator of the Group on Evolutionary Genomics from the Research Programme on Biomedical Informatics (GRIB) from IMIM and the UPF and an ICREA Professor, and with the collaboration of scientists from different centres at the PRBB (Barcelona Biomedical Research Park), has revealed there are hundreds of de novo genes originated in humans, many of which where unknown until now. Some of these genes are coded through small proteins that are expressed in the brain or in germinal cells.
28/01/2015 - General information
The project iPIE: Intelligence Led Assessment of Pharmaceuticals in the Environment starts on February 2015 with a kick off meeting at Barcelona Biomedical Research Park (PRBB) and the participation of the GRIB research groups of Integrative Biomedical Informatics (IBI) and PharmacoInformatics (PhI) of Institut Hospital del Mar d’Investigacions Mèdiques (IMIM)) and Pompeu Fabra University (UPF). It is often ignored that any drug administered to human patients ends up in the environment, either in the original form or as a mixture of drug metabolites. Testing the environmental impact of novel drug candidates is therefore important in order to early discard potentially dangerous ones. With a budget of 10.2 million euros and a duration of 4 years, the project iPIE aims to develop a predictive framework that utilise existing information and in silico models to support more intelligent environmental testing of pharmaceuticals in development and to prioritise legacy pharmaceuticals for full environmental risk assessment and/or environmental (bio) monitoring.
Més informació "Project iPIE: Testing the environmental impact of drugs"
18/11/2014 - General information
The platform for the analysis of human diseases and their genes DisGeNET, developed by the Integrative Biomedical Informatics research group at GRIB (IMIM-UPF) appears for the first time in the Linking Open Data (LOD) linking diagram. This type of diagram shows sets of data in Linked Data format, which is used by the World Wide Web to link structured and related data. Linked Data is the best way to showcase, share and connect data, information and knowledge on the semantic web through technologies such as Uniform Resource Identifiers (or URIs, web resource identifiers) andResource Description Framework (or RDF, a model to represent information in a structured way).
Més informació "DisGeNET included in the Linking Open Data (LOD) diagram"
27/11/2012 - General information
Two studies led by researchers from the neuroimaging research group at IMIM led by Òscar Vilarroya, and which also involved researchers from UAB and the Hospital de la Vall d’Hebron, have been cited in the “Consensus Report of the APA Work Group” as international reference works in the area of attention deficit and hyperactivity disorder (ADHD), conferring upon these researchers the status of world leaders in this field.
Més informació "IMIM researchers world leaders in neuroimaging and ADHD research"
12/09/2012 - General information
The project- based on a collaboration agreement between the Barcelona Science Park (PCB) and the companies SOM Biotech and Metasbio– will enable the discovery of new therapeutic applications of previously existing drugs (repurposing), especially in areas of great medical need and market potential, such as the central nervous system, oncology and orphan diseases.
23/07/2012 - General information
From the 27th of July until the 12th of August the London 2012 Olympics will be taking place. Once again, and thanks to an agreement between King’s College in London and the IMIM Foundation, as of the 23rd of July a group of technicians from the IMIM Bioanalysis and Analysis Services research group will join the Official Antidoping Laboratory of the London 2012 Olympics.
Més informació "The IMIM Antidoping Control Lab in London 2012"
21/06/2012 - General information
"Connect, partner and innovate". This is the slogan for the twentieth edition of the BIO International Convention, held 18 to 21 June 2012 in the city of Boston (Massachusetts, United States). BIO is the most important international business meeting in the biotechnology arena. This year, it will bring together more than 15,000 delegates from 65 countries, more than 900 exhibitors and 1,800 companies. In addition to the exhibition area, it also features a Business Forum for partnering meetings, which in 2011 generated more than 21,000 one-to-one meetings.
Més informació "GRIB participated at BIO Boston 2012, the top biotechnology convention in the world"
21/05/2012 - General information
After one week of intensive training, the closing event of the INBIOMEDvision Training Challenge successfully took place in Barcelona. This training gathered together two teams of 5 PhD students with different nationalities and scientific backgrounds (chemists, medical doctors, informatics, mathematics, biologists etc.) to work on two case studies related with health sciences during one week at the Monastery of Les Avellanes (Lleida, Spain).
15/03/2012 - General information
The European project EU contributions to the World Mental Health Survey Initiative (EU-WMH, 2009-2011) coordinated by Jordi Alonso, started with the goal of estimating the frequency, distribution and consequences of mental disorders in Europe, while increasing awareness and strengthening existing public initiatives on mental health in the fields of research and politics.
Més informació "Mental health in Europe: results of the European EU-WMH project"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
